New approaches for antigen discovery, production and delivery: vaccines for veterinary and human use

An overview of progress from empirical to rational design in modern vaccine development, with an emphasis on computational tools and immunoinformatics approaches

Vaccination remains the most effective strategy for preventing and controlling infectious diseases. Numerous conventional vaccines, especially live attenuated, inactivated (killed) microorganisms and subunit vaccines, lead to an effective induction of protective immune responses, mainly antibody-mediated responses against pathogens. However, it has become known that a wide range of highly dangerous pathogens are uncontrollable via conventional vaccination strategies. Recent advances in molecular biology, immunology, genetics, biochemistry, and bioinformatics have provided new prospects for vaccine development. As a result of these advances, several new strategies for vaccine design, development, and production have appeared. These strategies show advantages over conventional vaccines. In this review, we discuss some of the major novel approaches, including recombinant protein vaccines, live recombinant viral and bacterial vectors, DNA and RNA vaccines, reverse vaccinology and reverse genetics approaches. Moreover, we have described the recent progresses on computational tools and immunoinformatics approaches for identifying, designing, and developing new candidate vaccines.

Parenteral immunization of fish, Labeo rohita with Poly D, L-lactide-co-glycolic acid (PLGA) encapsulated antigen microparticles promotes innate and adaptive immune responses

Immunogenicity of different antigen preparations of outer membrane proteins (OMP) of Aeromonas hydrophila such as Poly d, l-lactide-co-glycolic acid (PLGA) microparticles, oil emulsion, neat OMP and bacterial whole cells were compared through intra-peritoneal injection in fish, Labeo rohita. Among these preparations, PLGA encapsulated antigen stimulated both innate and adaptive immune parameters and the immunogenicity exhibited by PLGA microparticles was significantly higher (p < 0.05) at both 21 and 42 days post-immunization suggesting that the above delivery system would be a novel antigen carrier for parenteral immunization in fish, Labeo rohita.

Genetic and proteomic analysis of the MHC class I repertoire from four ovine haplotypes

Immunity to livestock diseases can be studied directly in the target animal, but its elucidation is often constrained by the lack of major histocompatibility complex (MHC)-defined animals. To address this issue, we have established an MHC-defined sheep resource flock generated around four diverse MHC haplotypes. Initial characterisation of the repertoire of transcribed MHC class I genes identified three class I transcripts associated with each haplotype. Nucleotide sequence, transcript abundance and phylogenetic analysis indicated that they represent alleles at up to four polymorphic loci that vary in number between the different haplotypes. The functional significance of each of these genes is evaluated here using complementary molecular genetic and proteomic approaches. We determine which genes give rise to proteins that localise to the surface of transfected cells. In addition, we provide data to support the generation of expressed products, based on immunoprecipitation of class I products from animals homozygous for each of the four MHC haplotypes followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. This provides a clearer picture of the number of MHC class I loci in sheep and allows more rational prediction of their classical (class Ia) or non-classical (class Ib) nature. On the basis of the cellular localisation, phylogenetic and transcriptional analyses, we propose that the ovine MHC comprises a minimum of eight class I loci, with considerable variation between haplotypes.

Brucella spp. lumazine synthase: a novel antigen delivery system

Lumazine synthase from Brucella spp. (BLS) was evaluated as a protein carrier to improve antigen delivery of KETc1, one of the peptides of the anti-cysticercosis vaccine. KETc1 becomes antigenic, preserved its immunogenicity and its protective capacity when expressed as a recombinant chimeric protein using Brucella spp. lumazine synthase. KETc1 and BLS-KETc1 were not MHC H-2(d), H-2(k) nor H-2(b) haplotype-restricted albeit KETc1 is preferentially presented in the H-2(b) haplotype. These findings support that BLS is a potent new delivery system for the improvement of subunit vaccines.